Weight Loss Effect on Circulating Liver Enzymes
Status
Conditions
Treatments
Details and patient eligibility
About
To investigate weight loss effect with mild calorie restriction on circulating levels of liver enzymes in nondiabetic and overweight subjects with high visceral fat area [visceral fat area (VFA) at L4 ≥ 100 cm²].
Full description
A 12-week randomized, placebo-controlled study was conducted on 80 nondiabetic and overweight subjects with high VFA. The participants divided into two groups: 12-week mild calorie restriction (a 300 kcal/day intake reduction, n=40) or no treatment (control, n=40). The randomization was according to computer-generated block randomization (placebo:test = 1:1). Before and after intervention period, venous blood samples were obtained from the subjects, and biochemical parameters including circulating liver enzymes were measured.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Able to give informed consent
- 20-60 years old
- Males and females
- Overweight (25.0 kg/m²≤ BMI <30 kg/m²)
- Absence of pregnancy or breast-feeding
- Stable body weight (body weight change <1kg for 3 months before screening)
- High visceral fat (VFA) at L4 (VFA at L4 ≥100 cm²)
- Without hypertension, type 2 diabetes, cardiovascular disease, or thyroid disease
- No use medication affecting body weight, energy expenditure, or glucose control for the last 6 months
Exclusion criteria
- Prior history of Cushing syndrome or malignancy
- Prior history of liver disease including chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, or drug-induced liver disease
- Excess alcohol intake (based on WHO standard)
- History of intentional reduction in weight in the preceding 6 months
Trial design
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal